Mycobacteria/Nocardia Laboratory, University of Texas Health Science Center at Tyler, Tyler, Texas, USA
Mycobacteria/Nocardia Laboratory, University of Texas Health Science Center at Tyler, Tyler, Texas, USA.
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01947-20.
Infections caused by nontuberculous mycobacteria (NTM) are increasing globally. complex (MAC) and complex are the most frequently encountered NTM, and oral treatment options are extremely limited for these pathogens, especially for the complex. In this study, the potency of omadacycline, a new tetracycline derivative, was tested against 111 isolates of NTM. MIC testing was performed as recommended by the Clinical and Laboratory Standards Institute against 70 isolates of rapidly growing mycobacteria (RGM), of which >90% were tetracycline resistant. These included subsp. (20 isolates), subsp. (3), (15 isolates), (7 isolates), the group, including six doxycycline-resistant isolates (12 isolates), and the group, including four doxycycline-resistant isolates (10 isolates). Forty-one isolates of slowly growing mycobacteria (SGM), including 16 isolates of MAC, were also tested. Omadacycline was active against all RGM species, with MIC ranges of 0.004 to 0.25 and 0.06 to 1 μg/ml for 80% and 100% inhibition, respectively. For subsp. , MICs were 0.06 and 0.12 μg/ml with 80% and 100% inhibition, respectively. There was considerable trailing of the omadacycline endpoint with the RGM. MICs of tigecycline exhibited no trailing and were generally within 1 to 2 dilutions of the 100% inhibition omadacycline MICs. While there was no trailing observed in SGM, omadacycline MICs were higher (MIC range, 8 to >16 μg/ml; = 41), as previously noted with tigecycline. This study supports further research of omadacycline, including clinical trials, for the treatment of RGM infections, especially .
非结核分枝杆菌（NTM）引起的感染在全球范围内呈上升趋势。 复合群（MAC）和 复合群是最常遇到的 NTM，对于这些病原体，口腔治疗选择极其有限，特别是对于 复合群。在这项研究中，新型四环素衍生物奥马环素对 111 株 NTM 分离株的杀菌活性进行了测试。根据临床和实验室标准协会的建议进行 MIC 测试，针对 70 株快速生长分枝杆菌（RGM）进行测试，其中>90%对四环素耐药。这些包括 亚种。（20 株）、 亚种。（3）、 （15 株）、 （7 株）、包括 6 株强力霉素耐药株的 组（12 株）和包括 4 株强力霉素耐药株的 组（10 株）。41 株缓慢生长分枝杆菌（SGM），包括 16 株 MAC 也进行了测试。奥马环素对所有 RGM 种均具有活性，MIC 范围分别为 0.004 至 0.25 和 0.06 至 1μg/ml，分别为 80%和 100%抑制。对于 亚种。，MIC 分别为 0.06 和 0.12μg/ml，分别为 80%和 100%抑制。奥马环素对 RGM 的终点有明显的拖尾现象。替加环素的 MIC 没有拖尾，通常与 100%抑制奥马环素 MIC 相差 1 至 2 个稀释度。虽然在 SGM 中没有观察到拖尾现象，但奥马环素的 MIC 更高（MIC 范围为 8 至>16μg/ml；n=41），这与替加环素之前的观察结果一致。这项研究支持对奥马环素进行进一步研究，包括临床试验，以治疗 RGM 感染，特别是 。
